Overview

Safety Study of Single Administration Post-exposure Prophylaxis Treatment for Marburg Virus

Status:
Completed
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety and pharmacology of single administrations of AVI-6003, a post-exposure prophylaxis candidate treatment for Marburg virus.
Phase:
Phase 1
Details
Lead Sponsor:
Sarepta Therapeutics
Sarepta Therapeutics, Inc.
Collaborator:
United States Department of Defense